Genotyping of the cytochrome P450 2D6 4469 C>T polymorphism using SimpleProbes™

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 67, Issue 3, 2007, Pages 280-290

  Nielsen, K A ^a   Hansen, E Lyders ^a   Gille, S ^b  

^a DANISH EPILEPSY CENTRE   (Denmark)

^b TIB MOLBIOL GmbH   (Germany)

Author keywords

CYP2D6; Genotyping; SimpleProbes

Indexed keywords

CYTOCHROME P450 2D6; GENOMIC DNA;

ALLELE; ARTICLE; CAUCASIAN; CYTOCHROME P450 2D6 GENE; DNA POLYMORPHISM; FLUORESCENCE; GENE; GENE DELETION; GENOTYPE; HUMAN; MELTING POINT; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOLOGICAL AVAILABILITY; COSTS AND COST ANALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; DEBRISOQUIN; ENZYME ACTIVATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC TECHNIQUES; GENOTYPE; HUMANS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 34247349565     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510601039982     Document Type: Article

References (32)

1. Roots I, Gerloff T, Meisel C, Kirchheiner J, Goldammer M, Kaiser R, et al. Pharmacogenetics-based new therapeutic concepts. Drug Metabolism Rev 2004;36:617-38.
2. Daly AK. Pharmacogenetics of the cytochromes P450. Cur Top Med Chem 2004;4:1733-44.
3. Kirchheiner J, Brøsen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psych Scand 2001;104:173-92.
4. Wedlund PJ, deLeo J, Lexington K. Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence? Clin Pharm Ther 2004;75:373-5.
5. Rau T, Wohlleben G, Wuttke H, Thurauf N, Lunkenmeier J, Lanczik M, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin Pharm Ther 2004;75:386-93.
6. Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP219 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005;51:376-85.
7. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychol 2005;66:15-27.
8. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13.
9. Bertilsson L, Dahl M-L, Dalèn P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotrophic drugs. Br J Clin Pharmacol 2002;53:111-22.
10. Steen VM, Andreassen OA, Daly AK, Tefre T, Børresen A-L, Idle JR, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5:215-23.
11. Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 1996;6:319-28.
12. Johansson IJ, Lundquist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90:11825-9.
13. Johansson I, Lundqvist E, Dahl M-L, Ingelman-Sundberg M. PCR based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996;6:351-5.
14. Armstrong M, Idle JR, Daly AK. A polymorphic Cfo I site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction. Hum Genet 1993;91:616-17.
15. Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Guidice JM-L, et al. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 1995;5:373-84.
16. Chou W-H, Yan F-X, Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 2003;49:542-51.
17. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P450D6 (CYP2D6) phenotype assignment using a genotype algorithm based on allele frequency data. Pharmacogenetics 1999;9:669-82.
18. Stamer UM, Bayerer B, Wolf S, Hoeft A, Stüber F. Rapid and reliable method for cytochrome P450 2D6 genotyping. Clin Chem 2002;48:1412-17.
19. Løvlie R, Daly A, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996;392:30-4.
20. Bjerke J, Chang C-C, Schur C, Wong S, Nuwayhid N. Genotyping of cytochrome P450 2D6*4 mutation with fluorescent hybridization probes using LightCycler. In: Meuer S, Wittwer C, Nakagawara K-I, editors. Rapid cycle real-time PCR. New York: Springer; 2001. pp 105-10.
21. Kemp CA, Flanagan JU, van Eldik AJ, Marechal JD, Wolf CR, Roberts GCK, et al. Validation of model of cytochrome p450 2D6: an in silico tool for predicting metabolism and inhibition. J Med Chem 2005;47:5340-6.
22. James HM, Coller JK, Gillis D, Bahnisch J, Sallustio BC, Somogyi AA. A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. Intl J Clin Pharmacol Ther 2004;42:719-23.
23. Eriksson S, Berg LM, Wadelius M, Alderborn A. Cytochrome P450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing™ technology. Assay Drug Devel Tech 2002;1:49-59.
24. Zackrisson AL, Lindblon B. Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing. Eur J Clin Pharmacol 2003;59:521-6.
25. Murphy GM, Pollock BG, Kirshner MA, Pascoe N, Cheuk W, Mulsant BH, et al. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 2001;25:737-43.
26. Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, et al. Effects of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002;12:465-72.
27. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 2002;72:76-89.
28. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
29. Rasmussen JO, Christensen M, Svendsen JM, Skausig O, Hansen EL, Nielsen KA. CYP2D6 gene test in psychiatric patients and in healthy volunteers. Scand J Clin Lab Invest 2006;66:1-8.
30. Raimundoo S, Toscano C, Klein K, Fischer J, Griese E-U, Eichelbaum M, et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 CYP2D6 in white subjects. Clin Pharm Ther 2004;76:128-38.
31. Highsmith W Jr. SNPs for sale. Cheap! Clin Chem 2004;50:1296-8.
32. Zhou L, Myers AN, Vandersteen JG, Wang L, Wittwer CT. Closed-tube genotyping with unlabeled oligonucleotide probes and a saturating DNA dye. Clin Chem 2004;50:1328-35.